Shopping Cart 0
Cart Subtotal
AED 0

Colon Cancer - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 27525

Details

Colon Cancer-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer-Pipeline Review, H1 2018, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 12, 40, 3, 169, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 43 and 15 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 8

Colon Cancer-Overview 9

Colon Cancer-Therapeutics Development 10

Colon Cancer-Therapeutics Assessment 42

Colon Cancer-Companies Involved in Therapeutics Development 64

Colon Cancer-Drug Profiles 121

Colon Cancer-Dormant Projects 726

Colon Cancer-Discontinued Products 742

Colon Cancer-Product Development Milestones 743

Appendix 751


List Of Figure

List of Figures

Number of Products under Development for Colon Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Colon Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Colon Cancer-Pipeline by 3-V Biosciences Inc, H1 2018

Colon Cancer-Pipeline by 4P-Pharma SAS, H1 2018

Colon Cancer-Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Adamed Sp z oo, H1 2018

Colon Cancer-Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018

Colon Cancer-Pipeline by Aduro BioTech Inc, H1 2018

Colon Cancer-Pipeline by Advenchen Laboratories LLC, H1 2018

Colon Cancer-Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Colon Cancer-Pipeline by Affimed GmbH, H1 2018

Colon Cancer-Pipeline by AGV Discovery SAS, H1 2018

Colon Cancer-Pipeline by AIMM Therapeutics BV, H1 2018

Colon Cancer-Pipeline by AlfaSigma SpA, H1 2018

Colon Cancer-Pipeline by Alligator Bioscience AB, H1 2018

Colon Cancer-Pipeline by Ambrx Inc, H1 2018

Colon Cancer-Pipeline by Amgen Inc, H1 2018

Colon Cancer-Pipeline by AndroScience Corp, H1 2018

Colon Cancer-Pipeline by ANP Technologies Inc, H1 2018

Colon Cancer-Pipeline by Aphios Corp, H1 2018

Colon Cancer-Pipeline by Aptose Biosciences Inc, H1 2018

Colon Cancer-Pipeline by Arcus Biosciences Inc, H1 2018

Colon Cancer-Pipeline by Asana BioSciences LLC, H1 2018

Colon Cancer-Pipeline by aTyr Pharma Inc, H1 2018

Colon Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Colon Cancer-Pipeline by Batu Biologics Inc, H1 2018

Colon Cancer-Pipeline by Bayer AG, H1 2018

Colon Cancer-Pipeline by BCN Biosciences LLC, H1 2018

Colon Cancer-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Bicycle Therapeutics Ltd, H1 2018

Colon Cancer-Pipeline by BioCancell Ltd, H1 2018

Colon Cancer-Pipeline by Biogazelle NV, H1 2018

Colon Cancer-Pipeline by Blirt SA, H1 2018

Colon Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2018

Colon Cancer-Pipeline by Can-Fite BioPharma Ltd, H1 2018

Colon Cancer-Pipeline by CBT Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Celgene Corp, H1 2018

Colon Cancer-Pipeline by Cellective BioTherapy Inc, H1 2018

Colon Cancer-Pipeline by Celprogen Inc, H1 2018

Colon Cancer-Pipeline by Chem-Master International Inc, H1 2018

Colon Cancer-Pipeline by CytomX Therapeutics Inc, H1 2018

Colon Cancer-Pipeline by Cytune Pharma SAS, H1 2018

Colon Cancer-Pipeline by CZ BioMed Corp, H1 2018

Colon Cancer-Pipeline by Debiopharm International SA, H1 2018

Colon Cancer-Pipeline by DEKK-TEC Inc, H1 2018

Colon Cancer-Pipeline by Eli Lilly and Co, H1 2018

Colon Cancer-Pipeline by Enterome Bioscience SA, H1 2018

Colon Cancer-Pipeline by EntreChem SL, H1 2018

Colon Cancer-Pipeline by EnzymeBioSystems, H1 2018

Colon Cancer-Pipeline by Evotec AG, H1 2018

Colon Cancer-Pipeline by F-star Biotechnology Ltd, H1 2018

Colon Cancer-Pipeline by Felicitex Therapeutics Inc, H1 2018

Colon Cancer-Pipeline by Fujifilm Holdings Corporation, H1 2018

Colon Cancer-Pipeline by Fusion Pharmaceuticals Inc, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Colon Cancer Therapeutic Products under Development, Key Players in Colon Cancer Therapeutics, Colon Cancer Pipeline Overview, Colon Cancer Pipeline, Colon Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

4P-Pharma SAS

Actinium Pharmaceuticals Inc

Adamed Sp z oo

Adgero Biopharmaceuticals Holdings Inc

Aduro BioTech Inc

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affimed GmbH

AGV Discovery SAS

AIMM Therapeutics BV

AlfaSigma SpA

Alligator Bioscience AB

Ambrx Inc

Amgen Inc

AndroScience Corp

ANP Technologies Inc

Aphios Corp

Aptose Biosciences Inc

Arcus Biosciences Inc

Asana BioSciences LLC

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Batu Biologics Inc

Bayer AG

BCN Biosciences LLC

BeyondSpring Pharmaceuticals Inc

Bicycle Therapeutics Ltd

BioCancell Ltd

Biogazelle NV

Blirt SA

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Cellective BioTherapy Inc

Celprogen Inc

Chem-Master International Inc

CytomX Therapeutics Inc

Cytune Pharma SAS

CZ BioMed Corp

Debiopharm International SA

DEKK-TEC Inc

Eli Lilly and Co

Enterome Bioscience SA

EntreChem SL

EnzymeBioSystems

Evotec AG

F-star Biotechnology Ltd

Felicitex Therapeutics Inc

Fujifilm Holdings Corporation

Fusion Pharmaceuticals Inc

G1 Therapeutics Inc

GammaDelta Therapeutics Ltd

GlaxoSmithKline Plc

GlycaNova Norway AS

GlycoMimetics Inc

Glycotope GmbH

Grunenthal GmbH

Guangdong Zhongsheng Pharmaceutical Co Ltd

Halozyme Therapeutics Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Histogen Inc

HitGen LTD

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Immix BioPharma Inc

Immunotope Inc

IMPACT Therapeutics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Innopharmax Inc

Innovation Pharmaceuticals Inc

Intezyne Technologies Inc

Jasco Pharmaceuticals LLC

Jiangsu Kanion Pharmaceutical Co Ltd

Kadmon Corp LLC

Karyopharm Therapeutics Inc

Kineta Inc

Kringle Pharma Inc

Lipocure Ltd

Lixte Biotechnology Holdings Inc

Lupin Ltd

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Medicenna Therapeutics Corp

Merck KGaA

Merus NV

Molecular Targeting Technologies Inc

Mologen AG

Monopar Therapeutics Inc

Multimmune GmbH

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

OncoResponse Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Patrys Ltd

PharmaCyte Biotech Inc

Phenex Pharmaceuticals AG

Philogen SpA

Plexxikon Inc

Prosetta Biosciences Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

PTC Therapeutics Inc

Qu Biologics Inc

Redx Pharma Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Sareum Holdings Plc

Sensei Biotherapeutics Inc

Sirnaomics Inc

Somantix BV

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sphaera Pharma Pte Ltd

Spring Bank Pharmaceuticals Inc

Starpharma Holdings Ltd

Synergys Biotherapeutics Inc

Systimmune Inc

Takeda Pharmaceutical Co Ltd

Takis Srl

Theravectys SA

Tiziana Life Sciences Plc

Transgene Biotek Ltd

Triumvira Immunologics Inc

Tyg Oncology Ltd

Vaccinogen Inc

Vault Pharma Inc

Vernalis Plc

VG Life Sciences Inc

XOMA Corp

Yakult Honsha Co Ltd

Zenith Epigenetics Ltd

Company Profile

Company Profile Title

Colon Cancer-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer-Pipeline Review, H1 2018, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 12, 40, 3, 169, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 43 and 15 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 8

Colon Cancer-Overview 9

Colon Cancer-Therapeutics Development 10

Colon Cancer-Therapeutics Assessment 42

Colon Cancer-Companies Involved in Therapeutics Development 64

Colon Cancer-Drug Profiles 121

Colon Cancer-Dormant Projects 726

Colon Cancer-Discontinued Products 742

Colon Cancer-Product Development Milestones 743

Appendix 751


List Of Figure

List of Figures

Number of Products under Development for Colon Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Colon Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Colon Cancer-Pipeline by 3-V Biosciences Inc, H1 2018

Colon Cancer-Pipeline by 4P-Pharma SAS, H1 2018

Colon Cancer-Pipeline by Actinium Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Adamed Sp z oo, H1 2018

Colon Cancer-Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018

Colon Cancer-Pipeline by Aduro BioTech Inc, H1 2018

Colon Cancer-Pipeline by Advenchen Laboratories LLC, H1 2018

Colon Cancer-Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Colon Cancer-Pipeline by Affimed GmbH, H1 2018

Colon Cancer-Pipeline by AGV Discovery SAS, H1 2018

Colon Cancer-Pipeline by AIMM Therapeutics BV, H1 2018

Colon Cancer-Pipeline by AlfaSigma SpA, H1 2018

Colon Cancer-Pipeline by Alligator Bioscience AB, H1 2018

Colon Cancer-Pipeline by Ambrx Inc, H1 2018

Colon Cancer-Pipeline by Amgen Inc, H1 2018

Colon Cancer-Pipeline by AndroScience Corp, H1 2018

Colon Cancer-Pipeline by ANP Technologies Inc, H1 2018

Colon Cancer-Pipeline by Aphios Corp, H1 2018

Colon Cancer-Pipeline by Aptose Biosciences Inc, H1 2018

Colon Cancer-Pipeline by Arcus Biosciences Inc, H1 2018

Colon Cancer-Pipeline by Asana BioSciences LLC, H1 2018

Colon Cancer-Pipeline by aTyr Pharma Inc, H1 2018

Colon Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Colon Cancer-Pipeline by Batu Biologics Inc, H1 2018

Colon Cancer-Pipeline by Bayer AG, H1 2018

Colon Cancer-Pipeline by BCN Biosciences LLC, H1 2018

Colon Cancer-Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Bicycle Therapeutics Ltd, H1 2018

Colon Cancer-Pipeline by BioCancell Ltd, H1 2018

Colon Cancer-Pipeline by Biogazelle NV, H1 2018

Colon Cancer-Pipeline by Blirt SA, H1 2018

Colon Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2018

Colon Cancer-Pipeline by Can-Fite BioPharma Ltd, H1 2018

Colon Cancer-Pipeline by CBT Pharmaceuticals Inc, H1 2018

Colon Cancer-Pipeline by Celgene Corp, H1 2018

Colon Cancer-Pipeline by Cellective BioTherapy Inc, H1 2018

Colon Cancer-Pipeline by Celprogen Inc, H1 2018

Colon Cancer-Pipeline by Chem-Master International Inc, H1 2018

Colon Cancer-Pipeline by CytomX Therapeutics Inc, H1 2018

Colon Cancer-Pipeline by Cytune Pharma SAS, H1 2018

Colon Cancer-Pipeline by CZ BioMed Corp, H1 2018

Colon Cancer-Pipeline by Debiopharm International SA, H1 2018

Colon Cancer-Pipeline by DEKK-TEC Inc, H1 2018

Colon Cancer-Pipeline by Eli Lilly and Co, H1 2018

Colon Cancer-Pipeline by Enterome Bioscience SA, H1 2018

Colon Cancer-Pipeline by EntreChem SL, H1 2018

Colon Cancer-Pipeline by EnzymeBioSystems, H1 2018

Colon Cancer-Pipeline by Evotec AG, H1 2018

Colon Cancer-Pipeline by F-star Biotechnology Ltd, H1 2018

Colon Cancer-Pipeline by Felicitex Therapeutics Inc, H1 2018

Colon Cancer-Pipeline by Fujifilm Holdings Corporation, H1 2018

Colon Cancer-Pipeline by Fusion Pharmaceuticals Inc, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Colon Cancer Therapeutic Products under Development, Key Players in Colon Cancer Therapeutics, Colon Cancer Pipeline Overview, Colon Cancer Pipeline, Colon Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

4P-Pharma SAS

Actinium Pharmaceuticals Inc

Adamed Sp z oo

Adgero Biopharmaceuticals Holdings Inc

Aduro BioTech Inc

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affimed GmbH

AGV Discovery SAS

AIMM Therapeutics BV

AlfaSigma SpA

Alligator Bioscience AB

Ambrx Inc

Amgen Inc

AndroScience Corp

ANP Technologies Inc

Aphios Corp

Aptose Biosciences Inc

Arcus Biosciences Inc

Asana BioSciences LLC

aTyr Pharma Inc

Aurigene Discovery Technologies Ltd

Batu Biologics Inc

Bayer AG

BCN Biosciences LLC

BeyondSpring Pharmaceuticals Inc

Bicycle Therapeutics Ltd

BioCancell Ltd

Biogazelle NV

Blirt SA

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Cellective BioTherapy Inc

Celprogen Inc

Chem-Master International Inc

CytomX Therapeutics Inc

Cytune Pharma SAS

CZ BioMed Corp

Debiopharm International SA

DEKK-TEC Inc

Eli Lilly and Co

Enterome Bioscience SA

EntreChem SL

EnzymeBioSystems

Evotec AG

F-star Biotechnology Ltd

Felicitex Therapeutics Inc

Fujifilm Holdings Corporation

Fusion Pharmaceuticals Inc

G1 Therapeutics Inc

GammaDelta Therapeutics Ltd

GlaxoSmithKline Plc

GlycaNova Norway AS

GlycoMimetics Inc

Glycotope GmbH

Grunenthal GmbH

Guangdong Zhongsheng Pharmaceutical Co Ltd

Halozyme Therapeutics Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Histogen Inc

HitGen LTD

Horizon Pharma Plc

Hummingbird Bioscience Pte Ltd

Immix BioPharma Inc

Immunotope Inc

IMPACT Therapeutics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Innopharmax Inc

Innovation Pharmaceuticals Inc

Intezyne Technologies Inc

Jasco Pharmaceuticals LLC

Jiangsu Kanion Pharmaceutical Co Ltd

Kadmon Corp LLC

Karyopharm Therapeutics Inc

Kineta Inc

Kringle Pharma Inc

Lipocure Ltd

Lixte Biotechnology Holdings Inc

Lupin Ltd

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Medicenna Therapeutics Corp

Merck KGaA

Merus NV

Molecular Targeting Technologies Inc

Mologen AG

Monopar Therapeutics Inc

Multimmune GmbH

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

OncoResponse Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Patrys Ltd

PharmaCyte Biotech Inc

Phenex Pharmaceuticals AG

Philogen SpA

Plexxikon Inc

Prosetta Biosciences Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

PTC Therapeutics Inc

Qu Biologics Inc

Redx Pharma Plc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Sareum Holdings Plc

Sensei Biotherapeutics Inc

Sirnaomics Inc

Somantix BV

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sphaera Pharma Pte Ltd

Spring Bank Pharmaceuticals Inc

Starpharma Holdings Ltd

Synergys Biotherapeutics Inc

Systimmune Inc

Takeda Pharmaceutical Co Ltd

Takis Srl

Theravectys SA

Tiziana Life Sciences Plc

Transgene Biotek Ltd

Triumvira Immunologics Inc

Tyg Oncology Ltd

Vaccinogen Inc

Vault Pharma Inc

Vernalis Plc

VG Life Sciences Inc

XOMA Corp

Yakult Honsha Co Ltd

Zenith Epigenetics Ltd